Workboat Indexes

Ipsen Sa S/Adr (OP:IPSEY)

44.14 +3.68 (+9.10%)

Streaming Delayed Price Updated: 11:26 AM EST, Feb 12, 2026 Add to My Watchlist

Price and Volume

Volume	176
Open	44.14
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	40.46
Today's Range	44.14 - 44.14
52wk Range	25.11 - 41.21
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal ↗

July 13, 2024

In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson.

Via Talk Markets

FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo ↗

June 11, 2024

The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability...

Via Benzinga

Performance

YTD	+28.5%	+28.5%
1 Month	+17.5%	+17.5%
3 Month	+15.4%	+15.4%
6 Month	+39.6%	+39.6%
1 Year	+37.9%	+37.9%

More News

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

November 10, 2023

From Virtual Investor Conferences

Via GlobeNewswire

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Via InvestorPlace

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

November 01, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗

August 21, 2023

Via Benzinga

Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class ↗

June 30, 2023

Via Benzinga

Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients ↗

June 30, 2023

Via Benzinga

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur ↗

May 22, 2023

Via Benzinga

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023

May 09, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

May 18, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.

January 27, 2023

From Ipsen

Via Business Wire

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI

January 20, 2023

From Ipsen

Via Business Wire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023

May 15, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Why These Two Biotech Stocks Blasted Higher This Week ↗

January 13, 2023

Via The Motley Fool

2 Tiny Nasdaq Stocks Making Major Merger Moves Monday ↗

January 09, 2023

Via The Motley Fool

France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline ↗

January 09, 2023

Via Benzinga

Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

January 09, 2023

From Ipsen

Via Business Wire

Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

December 23, 2022

From Ipsen

Via Business Wire

Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗

December 09, 2022

Via Benzinga

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy

December 08, 2022

From Ipsen

Via Business Wire

Why Merrimack Shares Are Surging Over 200% Today? ↗

November 09, 2022

Via Benzinga

Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

November 09, 2022

From Ipsen

Via Business Wire

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

Via Benzinga

Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance

October 27, 2022

From Ipsen

Via Business Wire

Frequently Asked Questions

Is Ipsen Sa S/Adr publicly traded?

Yes, Ipsen Sa S/Adr is publicly traded.

What exchange does Ipsen Sa S/Adr trade on?

Ipsen Sa S/Adr trades on the OTC Traded

What is the ticker symbol for Ipsen Sa S/Adr?

The ticker symbol for Ipsen Sa S/Adr is IPSEY on the OTC Traded

What is the current price of Ipsen Sa S/Adr?

The current price of Ipsen Sa S/Adr is 44.14

When was Ipsen Sa S/Adr last traded?

The last trade of Ipsen Sa S/Adr was at 02/12/26 11:26 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Workboat Indexes

Ipsen Sa S/Adr (OP:IPSEY)

Price and Volume

Top News

Performance

More News

Frequently Asked Questions

Burgum promises to appeal wind rulings; Nova Scotia, Massachusetts make own deal

Coast Guard completes last contract awards for 11 Arctic cutters

Saltchuk to acquire Great Lakes Dredge & Dock

Coast Guard’s OPC program plagued by growing delays and costs